Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,565.00GBp
23 Jan 2019
Change (% chg)

9.00 (+0.58%)
Prev Close
1,556.00
Open
1,543.00
Day's High
1,568.50
Day's Low
1,530.00
Volume
105,036
Avg. Vol
524,858
52-wk High
2,089.00
52-wk Low
814.20

Latest Key Developments (Source: Significant Developments)

Hikma Announces Agreement With Sciecure Pharma
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ANNOUNCES AGREEMENT WITH SCIECURE PHARMA.SCIECURE EXPECTS TO FILE THIS PRODUCT FOR APPROVAL WITH US FOOD AND DRUG ADMINISTRATION IN EARLY 2019.AGREEMENT PROVIDES CO EXCLUSIVE RIGHTS TO SELL ONE OF SCIECURE'S NICHE INJECTABLE ANTI-VIRAL MEDICINES ACROSS US FOR A MINIMUM OF EIGHT YEARS.DEAL HAS OPTION TO EXTEND PARTNERSHIP WITH SCIECURE FOR AN ADDITIONAL TWO YEARS.  Full Article

Joint Venture Between Gordon Brothers, New Mill Capital Acquired Three Buildings From Hikma Pharmaceuticals
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Hikma Pharmaceuticals PLC ::GORDON BROTHERS - JOINT VENTURE BETWEEN GORDON BROTHERS, NEW MILL CAPITAL ACQUIRED THREE BUILDINGS FROM HIKMA PHARMACEUTICALS IN EATONTOWN, NJ.  Full Article

Hikma Announces Agreement With Vectura
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA ANNOUNCES AGREEMENT WITH VECTURA.UPON SIGNING, HIKMA WILL MAKE AN UPFRONT PAYMENT OF $15 MILLION TO VECTURA.VECTURA WILL BE RESPONSIBLE FOR, AND FUND, INITIAL DEVICE AND FORMULATION DEVELOPMENT.DEAL FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF GENERIC VERSIONS OF GSK'S ELLIPTA PORTFOLIO.UPON TRANSFER OF 1ST PRODUCT TO CO'S MANUFACTURING FACILITY, WILL MAKE $5 MILLION MILESTONE PAYMENT TO VECTURA.THEREAFTER, HIKMA WILL MAKE MILESTONE PAYMENTS OF UP TO $75 MILLION AT VARIOUS STAGES OF DEVELOPMENT.VECTURA WILL CONTRIBUTE UP TO $70 MILLION TOWARDS HIKMA'S DEVELOPMENT ACTIVITIES FOR PORTFOLIO.HIKMA PHARMACEUTICALS - VECTURA'S CONTRIBUTION TO BE MADE THROUGH REDUCED PROFIT SHARE MECHANISM FOLLOWING COMMERCIAL LAUNCH OF FIRST PRODUCT.  Full Article

Hikma Pharmaceuticals Raises Guidance For Injectables, Generics Businesses For Full Year
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT 174 MILLION USD VERSUS 113 MILLION USD YEAR AGO.H1 REVENUE 989 MILLION USD VERSUS 895 MILLION USD YEAR AGO.INTERIM DIVIDEND 0.12 USDPER SHARE.GUIDANCE RAISED FOR INJECTABLES AND GENERICS BUSINESSES AND REITERATED FOR BRANDED BUSINESS.RAISE GUIDANCE FOR BOTH OUR INJECTABLES AND GENERICS BUSINESSES FOR FULL YEAR.NOW EXPECT FULL YEAR INJECTABLES REVENUE TO BE IN RANGE OF $775 MILLION TO $825 MILLION.EXPECT GENERICS FULL YEAR REVENUE TO BE IN RANGE OF $600 MILLION TO $650 MILLION.EXPECT BRANDED REVENUES TO BE HIGHER IN SECOND HALF OF YEAR.EXPECT FULL YEAR BRANDED REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS.DON'T EXPECT SAME DEMAND FOR SOME OF OUR INJECTABLE PRODUCTS TO CONTINUE INTO 2019.NOT CLEAR HOW LONG INJECTABLE OPIOIDS SHORTAGES WILL PERSIST; DON'T EXPECT TO SEE SAME LEVEL OF DEMAND CONTINUE INTO 2019.MENA INJECTABLES REVENUE WAS $51 MILLION IN H1 2018, UP 46%.IN H1 2018, GLOBAL INJECTABLES REVENUE INCREASED BY 14% TO $414 MILLION.CONTINUE TO EXPECT GROUP CAPITAL EXPENDITURE IN RANGE OF $120 MILLION TO $140 MILLION IN 2018.  Full Article

Acorda Updates On Litigation With Mylan, Teva, West-Ward Pharma & Hikma
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS - UPDATES ON LITIGATION WITH MYLAN, TEVA, WEST-WARD PHARMACEUTICALS INTERNATIONAL & HIKMA PHARMACEUTICALS USA.ACORDA THERAPEUTICS - TERMS OF SETTLEMENT AGREEMENT WITH MYLAN AND INTERIM AGREEMENTS WITH TEVA AND HIKMA ARE OTHERWISE CONFIDENTIAL.ACORDA THERAPEUTICS - MYLAN WILL BE PERMITTED TO MARKET ITS GENERIC VERSION OF AMPYRA IN U.S. SOMETIME IN 2025/EARLIER AS PER A CONDITIONED SETTLEMENT WITH CO.ACORDA THERAPEUTICS - SIGNED INTERIM AGREEMENT WITH TEVA CONCERNING PATENT LITIGATION RELATING TO AMPYRA THAT ADDRESSES PERIOD OF TIME UNTIL AUG 31.ACORDA THERAPEUTICS SAYS ALSO SIGNED INTERIM AGREEMENT WITH HIKMA CONCERNING THEIR PATENT LITIGATION RELATING TO AMPYRA - SEC FILING.  Full Article

Hikma Pharmaceuticals Says U.S. Business Releases Hydromorphone To Hospital Customers
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Hikma Pharmaceuticals PLC ::CO'S US BUSINESS RELEASING "SIGNIFICANT QUANTITIES" OF HYDROMORPHONE TO US HOSPITAL CUSTOMERS TO HELP WITH SHORTAGE OF INJECTABLE OPIOIDS.RELEASED MORE THAN 5 MILLION HYDROMORPHONE 2ML VIALS TO US HOSPITALS IN JUNE, EXPECTS TO RELEASE ANOTHER THREE MILLION VIALS IN JULY.  Full Article

Hikma Enters Licensing Partnership With Perrigo
Monday, 9 Jul 2018 

July 9 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ENTERS LICENSING PARTNERSHIP WITH PERRIGO.SIGNED LICENSING AND DISTRIBUTION AGREEMENT WITH OMEGA PHARMA TRADING NV.HIKMA HAS EXCLUSIVE RIGHT TO LICENSE AND DISTRIBUTE MORE THAN 30 CONSUMER HEALTHCARE PRODUCTS IN ALL ITS MENA MARKETS.IN ADDITION, HIKMA HAS RIGHT OF FIRST REFUSAL TO FULL RANGE OF PERRIGO'S OTC MEDICINES IN MENA REGION.  Full Article

Hikma Pharmaceuticals Reiterate Ourtlook For Generics 2018 Revenues In $550-$600 mln Range
Friday, 18 May 2018 

May 18 (Reuters) - Hikma Pharmaceuticals PLC ::REITERATE EXPECTATIONS FOR GENERICS REVENUES IN 2018 IN RANGE OF $550 MILLION TO $600 MILLION.FOR FULL YEAR, CONTINUE TO EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $750 MILLION TO $800 MILLION.CONTINUE TO EXPECT COMPETITION TO ACCELERATE OVER COURSE OF YEAR IN INJECTABLES.REITERATE GUIDANCE FOR FULL YEAR.FOR FULL YEAR, WE CONTINUE TO EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $750 MILLION TO $800 MILLION.FOR FULL YEAR CONTINUE TO EXPECT CORE INJECTABLES OPERATING MARGIN TO RETURN TO MORE NORMALISED LEVELS IN LOW TO MID 30S.CONTINUE TO FOCUS ON OPTIMISING COST BASE, REMAIN ON TRACK TO COMPLETE CONSOLIDATION OF MANUFACTURING AND DISTRIBUTION FACILITIES IN H2.IN 2017, EXPECT STRONGER SECOND HALF, REFLECTING USUAL SEASONALITY OF THIS BUSINESS IN BRANDED.DURING QUARTER INITIATED REPEAT CLINICAL ENDPOINT STUDY FOR GENERIC ADVAIR DISKUS.CONTINUE TO EXPECT BRANDED REVENUE GROWTH FOR FULL YEAR TO BE IN MID-SINGLE DIGITS IN CONSTANT CURRENCY.STUDY FOR GENERIC ADVAIR STUDY IS PROCEEDING AS PLANNED, EXPECT TO SUBMIT RESPONSE TO FDA WITH NEW CLINICAL DATA AS EARLY AS POSSIBLE IN 2019.AS IN 2017, WE EXPECT A STRONGER SECOND HALF IN BRANDED.CONTINUE TO EXPECT BRANDED REVENUE GROWTH FOR FULL YEAR TO BE IN MID-SINGLE DIGITS.  Full Article

Hikma Signs Licensing Agreement With Rovi For Enoxaparin Biosimilar
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Hikma Pharmaceuticals Plc ::SAYS EXPANDS LICENSING AGREEMENT WITH ROVI.SIGNED A LICENSING AGREEMENT WITH LABORATORIOS FARMACEÚTICOS ROVI SA FOR THEIR ENOXAPARIN BIOSIMILAR.UNDER TERMS OF AGREEMENT, HIKMA HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET ENOXAPARIN ACROSS ITS MENA MARKETS.  Full Article

Vanda Pharmaceuticals Wins Appeal Case On Fanapt
Friday, 13 Apr 2018 

April 13 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA WINS APPEAL CASE ON FANAPT®.U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT.'610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027.  Full Article

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.